The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

This national approval was granted after an Access Consortium new active substance work-sharing initiative (NASWSI) procedure ...

Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...